Zobrazeno 1 - 10
of 233
pro vyhledávání: '"Fumihiko, Sakai"'
Autor:
Michel Lanteri-Minet, Elizabeth Leroux, Zaza Katsarava, Richard B. Lipton, Fumihiko Sakai, Manjit Matharu, Kristina Fanning, Aubrey Manack Adams, Katherine Sommer, Michael Seminerio, Dawn C. Buse
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Objective To assess rates of traversing barriers to care to access optimal clinical outcomes in people with migraine internationally. Background People in need of medical care for migraine should consult a health care professional knowledgea
Externí odkaz:
https://doaj.org/article/35d3951a2ed94226982c1beef0ccd5ab
Autor:
Takao Takeshima, Koichi Hirata, Hisaka Igarashi, Fumihiko Sakai, Hiromi Sano, Hiroyuki Kondo, Yoshiyuki Shibasaki, Nobuyuki Koga
Publikováno v:
BMC Neurology, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Surveys using questionnaires to collect epidemiologic data may be subject to misclassification. Here, we analyzed a headache questionnaire to evaluate which questions led to a classification other than migraine. Methods Anonymized
Externí odkaz:
https://doaj.org/article/f1bbacc457f54f98803ae1e77a452163
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
ObjectiveThis study aimed to describe the migraine burden and healthcare utilization in the context of headache frequency using nationwide claims data linked to online survey data previously collected in Japan.BackgroundIt has been shown that increas
Externí odkaz:
https://doaj.org/article/5ea0677abc8245cfb1882c9da8a13d89
Autor:
Mamoru Shibata, Kazuki Fujita, Eri Hoshino, Kazushi Minami, Kenzo Koizumi, Satoshi Okada, Fumihiko Sakai
Publikováno v:
BMC Neurology, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Although randomized controlled trials (RCTs) have shown that calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies (CGRP mAbs) are an efficacious and safe therapeutic modality for migraine prevention, their clinica
Externí odkaz:
https://doaj.org/article/bd2bb529edd741c8bfe0d6be24e61b3d
Autor:
Junichi Higuchi, Masaki Kurogochi, Toshiyuki Yamaguchi, Noriki Fujio, Sho Mitsuduka, Yuko Ishida, Hirofumi Fukudome, Noriko Nonoyama, Masayuki Gota, Mamoru Mizuno, Fumihiko Sakai
Publikováno v:
Foods, Vol 13, Iss 17, p 2792 (2024)
Sialyl glycans have several biological functions. We have previously reported on the preparation and bifidogenic activity of milk-derived sialylglycopeptide (MSGP) concentrate containing sialyl O-glycans. The current study qualitatively and quantitat
Externí odkaz:
https://doaj.org/article/f54d5ff0107e4153a87275adfd44561d
Autor:
Mamoru Shibata, Kazuki Fujita, Eri Hoshino, Kazushi Minami, Kenzo Koizumi, Satoshi Okada, Fumihiko Sakai
Publikováno v:
BMC Neurology, Vol 24, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/b94cc6df3a514ae28f84b01ce0ce17e8
Autor:
Koichi Hirata, Fumihiko Sakai, Miki Hasebe, Takao Takeshima, Yotaro Numachi, Ryuji Yoshida, Reija Koukakis, Daishi Yui, Gabriel Paiva da Silva Lima, Sunfa Cheng
Publikováno v:
BMJ Open, Vol 13, Iss 8 (2023)
Objectives To evaluate the 1-year efficacy and safety of once-monthly erenumab 70 mg following a 24-week double-blind treatment period (DBTP) of a phase III randomised study of Japanese patients with episodic migraine (EM) or chronic migraine (CM).De
Externí odkaz:
https://doaj.org/article/27770103ef744fe59f643d1255f4c4ec
Autor:
Fumihiko Sakai, Koichi Hirata, Hisaka Igarashi, Takao Takeshima, Takeo Nakayama, Hiromi Sano, Hiroyuki Kondo, Yoshiyuki Shibasaki, Nobuyuki Koga
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-17 (2022)
Abstract Background Migraine is a chronic disease characterized by episodic headache attacks. No recent studies have, however been conducted on the epidemiology of migraine or the treatment landscape in Japan. This study was conducted as a fact-findi
Externí odkaz:
https://doaj.org/article/60e8ed30266742d880ac7ff4413a1488
Autor:
Koichi Hirata, Fumihiko Sakai, Takao Takeshima, Noboru Imai, Yasuhiko Matsumori, Ryuji Yoshida, Yotaro Numachi, Cheng Peng, Daniel D. Mikol, Sunfa Cheng
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-9 (2021)
Abstract Background These subgroup analyses of a Phase 3, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of erenumab 70 mg in Japanese migraine patients with/without prior preventive treatment failure(s) (“fail
Externí odkaz:
https://doaj.org/article/7516175e8dab45fcbabc0355ccc7d7dd
Disability, quality of life, productivity impairment and employer costs of migraine in the workplace
Autor:
Toshihiko Shimizu, Fumihiko Sakai, Hitoshi Miyake, Tomofumi Sone, Mitsuhiro Sato, Satoshi Tanabe, Yasuhiro Azuma, David W. Dodick
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-11 (2021)
Abstract Background Migraine is the leading cause of days lost due to disability in the world among people less than 50 years of age. There is a paucity of evidence on the impact of migraine and other headache disorders and the cost and productivity
Externí odkaz:
https://doaj.org/article/228f898040ac48158a05fb7a7af295ae